{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T07:18:33Z","timestamp":1788247113077,"version":"build-2803163510"},"reference-count":0,"publisher":"American Association for Cancer Research (AACR)","issue":"9","content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,9,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Nearly 11 years after T-VEC became the first oncolytic virus approved in a major market, the closest candidate to follow it\u2014Replimune\u2019s RP1, now facing an FDA advisory committee\u2014remains a locally injected herpesvirus for melanoma, underscoring how little the field has advanced. Researchers blame a stack of unresolved obstacles\u2014flawed trial designs, mistimed drug combinations, tumor defenses, such as hypoxia, and the inability to deliver most viruses intravenously\u2014even as smarter sequencing, neoadjuvant approaches, and a bladder-cancer virus near approval hint at renewed momentum.<\/jats:p>","DOI":"10.1158\/2159-8290.cd-nw2026-0080","type":"journal-article","created":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T07:34:27Z","timestamp":1785137667000},"page":"OF1-OF1","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Oncolytic Virotherapy, Long Stalled, Nears Second Approval"],"prefix":"10.1158","volume":"16","member":"1086","published-online":{"date-parts":[[2026,7,27]]},"container-title":["Cancer Discovery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerdiscovery\/article\/16\/9\/OF1\/787082\/Oncolytic-Virotherapy-Long-Stalled-Nears-Second","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerdiscovery\/article\/16\/9\/OF1\/787082\/Oncolytic-Virotherapy-Long-Stalled-Nears-Second","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T07:08:59Z","timestamp":1788246539000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerdiscovery\/article\/16\/9\/OF1\/787082\/Oncolytic-Virotherapy-Long-Stalled-Nears-Second"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,27]]},"references-count":0,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,7,27]]},"published-print":{"date-parts":[[2026,9,1]]}},"URL":"https:\/\/doi.org\/10.1158\/2159-8290.cd-nw2026-0080","relation":{},"ISSN":["2159-8274","2159-8290"],"issn-type":[{"value":"2159-8274","type":"print"},{"value":"2159-8290","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,27]]}}}